Novo Nordisk launches Ozempic, Fiasp in U.S.
PLAINSBORO, N.J. — Novo Nordisk has released two new diabetes medications, Ozempic (semaglutide injection 0.5 mg and 1 mg) and Fiasp (insulin aspart injection 100 units/ml), to U.S. pharmacies. Both medications gained Food and Drug Administration approval in 2017 and mark the latest advancements to Novo Nordisk’s diabetes portfolio, the company said Monday. Ozempic is a
